Literature DB >> 27249081

Comparative risk of seizure with use of first- and second-generation antipsychotics in patients with schizophrenia and mood disorders.

Chi-Shin Wu1,2, Sheng-Chang Wang, I-Jin Yeh, Shi-Kai Liu.   

Abstract

OBJECTIVE: To compare the risk of antipsychotic-related seizure (ARS) by identifying seizures first diagnosed within 12 months after starting new antipsychotics, using a 12-year total population health claims database from Taiwan.
METHODS: Seizure events were identified through emergency department visits or hospitalization with a diagnosis of convulsion (ICD-9-CM: 780.3) or epilepsy (ICD-9-CM: 345). Subjects had an ICD-9-CM diagnosis of schizophrenia, bipolar disorders, or major depressive disorders. Incidence rates of ARS were calculated by person-years of exposure. The ARS risk, adjusted for patient characteristics and medical conditions, of individual antipsychotics versus risperidone was examined by high-dimensional propensity score stratification analyses, followed by sensitivity analyses.
RESULTS: The overall 1-year incidence rate of ARS was 9.6 (95% CI, 8.8-10.4) per 1,000 person-years (550 ARS events among 288,397 new antipsychotic users). First-generation antipsychotics were marginally associated with a higher ARS risk than second-generation antipsychotics (adjusted hazard ratio [aHR] = 1.34; 95% CI, 0.99-1.81; P = .061). Most antipsychotics, first- or second-generation, had comparable ARS risks versus risperidone. Notably, clozapine (aHR = 3.06; 95% CI, 1.40-6.71), thioridazine (aHR = 2.90; 95% CI, 1.65-5.10), chlorprothixene (aHR = 2.60; 95% CI, 1.04-6.49), and haloperidol (aHR = 2.34; 95% CI, 1.48-3.71) had higher ARS risks than risperidone, whereas aripiprazole (aHR = 0.41; 95% CI, 0.17-1.00; P = .050) had a marginally lower ARS risk. Sensitivity analyses largely confirmed such findings.
CONCLUSIONS: Higher vigilance for ARS is warranted during use of clozapine, chlorprothixene, thioridazine, and haloperidol. The possible lower ARS risk associated with aripiprazole can be clinically significant but needs to be confirmed by larger-scale systematic studies. The comparative ARS risks of antipsychotics supplement empirical knowledge for making judicious choices in prescribing antipsychotics. © Copyright 2016 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27249081     DOI: 10.4088/JCP.15m09898

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  12 in total

Review 1.  Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine.

Authors:  Domenico De Berardis; Gabriella Rapini; Luigi Olivieri; Domenico Di Nicola; Carmine Tomasetti; Alessandro Valchera; Michele Fornaro; Fabio Di Fabio; Giampaolo Perna; Marco Di Nicola; Gianluca Serafini; Alessandro Carano; Maurizio Pompili; Federica Vellante; Laura Orsolini; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Ther Adv Drug Saf       Date:  2018-02-06

2.  [Convulsive status epilepticus as a possible symptom of COVID-19 in a patient with intellectual disability and autistic spectrum disorder].

Authors:  C Peña-Salazar; M López Cuiña; V Chavarría; B Robles Olmo
Journal:  Neurologia       Date:  2020-07-31       Impact factor: 3.109

3.  Risk of seizures associated with antipsychotic treatment in pediatrics with psychiatric disorders: a nested case-control study in Korea.

Authors:  Soo Min Jeon; Susan Park; Dohoon Kim; Jin-Won Kwon
Journal:  Eur Child Adolesc Psychiatry       Date:  2020-04-07       Impact factor: 4.785

Review 4.  Drug Treatment of Epilepsy Neuropsychiatric Comorbidities in Children.

Authors:  Gregory L Holmes
Journal:  Paediatr Drugs       Date:  2020-11-24       Impact factor: 3.022

Review 5.  Psychopharmacology of COVID-19.

Authors:  Melanie Bilbul; Patricia Paparone; Anna M Kim; Shruti Mutalik; Carrie L Ernst
Journal:  Psychosomatics       Date:  2020-05-18       Impact factor: 2.386

6.  Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial.

Authors:  Christoph U Correll; Robert E Davis; Michal Weingart; Jelena Saillard; Cedric O'Gorman; John M Kane; Jeffrey A Lieberman; Carol A Tamminga; Sharon Mates; Kimberly E Vanover
Journal:  JAMA Psychiatry       Date:  2020-04-01       Impact factor: 21.596

7.  Effects of Atypical Antipsychotics, Clozapine, Quetiapine and Brexpiprazole on Astroglial Transmission Associated with Connexin43.

Authors:  Kouji Fukuyama; Motohiro Okada
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

Review 8.  Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.

Authors:  Marco Solmi; Andrea Murru; Isabella Pacchiarotti; Juan Undurraga; Nicola Veronese; Michele Fornaro; Brendon Stubbs; Francesco Monaco; Eduard Vieta; Mary V Seeman; Christoph U Correll; André F Carvalho
Journal:  Ther Clin Risk Manag       Date:  2017-06-29       Impact factor: 2.423

Review 9.  A Working Hypothesis Regarding Identical Pathomechanisms between Clinical Efficacy and Adverse Reaction of Clozapine via the Activation of Connexin43.

Authors:  Motohiro Okada; Kouji Fukuyama; Takashi Shiroyama; Masahiko Murata
Journal:  Int J Mol Sci       Date:  2020-09-24       Impact factor: 5.923

10.  [Convulsive status epilepticus as a possible symptom of COVID-19 in a patient with intellectual disability and autistic spectrum disorder].

Authors:  C Peña-Salazar; M López Cuiña; V Chavarría; B Robles Olmo
Journal:  Neurologia (Engl Ed)       Date:  2020-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.